{"gene":"ADA","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1985,"finding":"The human ADA gene is 32 kb long, split into 12 exons, and its promoter region lacks TATA and CAAT boxes but is extremely G/C-rich (82%), containing SP1-binding motifs (GGGCGGG); a 135 bp upstream sequence was shown to have promoter activity in functional assays.","method":"Cosmid clone isolation, DNA sequencing, functional promoter assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — direct sequencing of the gene and functional promoter assay in original characterization paper","pmids":["3839456"],"is_preprint":false},{"year":1986,"finding":"The complete human ADA gene sequence confirmed 12 exons over 36,741 bp, with a G/C-rich promoter lacking TATA/CAAT boxes containing six SP1 binding site homologs (GGGCGGG), and defined all intron-exon boundaries.","method":"DNA sequencing of overlapping lambda phage clones","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — complete gene sequence with functional annotation","pmids":["3028473"],"is_preprint":false},{"year":1984,"finding":"ADA deficiency in ADA-SCID cells is not due to transcriptional or translational defects but to subtle changes in protein configuration affecting both enzymatic and immunological characteristics, as ADA-specific mRNA from SCID cells could be translated in vitro into a protein of normal molecular weight that lacked immunoprecipitability with ADA antiserum.","method":"Northern blot analysis, in vitro translation, immunoprecipitation","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (translation assay + immunoprecipitation) demonstrating protein-level defect","pmids":["6198631"],"is_preprint":false},{"year":1984,"finding":"The human ADA gene was regionally localized to chromosome 20q13.2–qter by somatic cell hybridization using a human cell line with a 17/20 balanced translocation.","method":"Somatic cell hybridization, enzyme assay","journal":"Annals of human genetics","confidence":"High","confidence_rationale":"Tier 2 — direct chromosomal localization confirmed by hybrid clone analysis","pmids":["6370091"],"is_preprint":false},{"year":1993,"finding":"ADA directly associates with CD26 (dipeptidyl peptidase IV, DPPIV) on the T cell surface; this 43 kDa protein was identified as ADA by amino acid sequence analysis and confirmed by immunoprecipitation, with binding mediated through the extracellular domain of CD26.","method":"Amino acid sequencing, immunoprecipitation, in vitro binding assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical identification by sequencing plus reciprocal binding assay, highly cited foundational paper","pmids":["8101391"],"is_preprint":false},{"year":1997,"finding":"ADA functions as an ectoenzyme on the cell surface by binding to membrane proteins including CD26 and A1 adenosine receptors (A1R); surface-bound ADA transmits signals upon interaction with CD26 or A1R, acting as a co-stimulatory molecule that facilitates specific signaling events, and its heterogeneous distribution in the nervous system suggests a neuroregulatory role.","method":"Cell surface binding studies, signal transduction assays, immunohistochemistry","journal":"Progress in neurobiology","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple binding and signaling assays but largely review/synthesis of experimental work","pmids":["9247966"],"is_preprint":false},{"year":2005,"finding":"ADA bound to CD26 on T cells interacts with an ADA-anchoring protein on dendritic cells to form a costimulatory signal at the immunological synapse; this costimulation was not due to ADA enzymatic activity but to protein-protein interaction, and potentiated T cell proliferation and production of IFN-γ, TNF-α, and IL-6 by 3- to 34-fold.","method":"Autologous T cell/dendritic cell coculture, colocalization microscopy, cytokine measurement, EC50 analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (colocalization, functional assays, enzymatic activity controls) replicated across cell types","pmids":["15983379"],"is_preprint":false},{"year":2006,"finding":"During hypoxia, endothelial ADA expression and activity are induced, and CD26 is coordinately upregulated to localize ADA activity at the endothelial cell surface; ADA surface binding was blocked by gp120 (which competes for ADA-CD26 binding), and pharmacological ADA inhibition with deoxycoformycin enhanced adenosine-mediated protection (reduced vascular leak and neutrophil accumulation) in murine hypoxia models.","method":"Microarray, in vitro/in vivo hypoxia models, protein expression, ADA activity assay, gp120 competition, deoxycoformycin pharmacological inhibition, plasma ADA activity in pediatric patients","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vitro and in vivo methods with mechanistic follow-up including pharmacological inhibition and patient samples","pmids":["16670267"],"is_preprint":false},{"year":2008,"finding":"In ADA-SCID patients, CD4+ T cells have severely compromised TCR/CD28-driven proliferation associated with intrinsically reduced ZAP-70 phosphorylation, Ca2+ flux, and ERK1/2 signaling, and defective CREB and NF-κB transcriptional activity; exposure to 2'-deoxyadenosine additionally inhibits T cell activation via aberrant A2A adenosine receptor signaling and PKA hyperactivation, or induces apoptosis at higher doses; gene therapy restored these biochemical signaling events and T cell functions.","method":"Phosphorylation assays, Ca2+ flux measurements, ERK1/2 signaling, transcription factor assays, apoptosis assays, receptor signaling pharmacology, comparison pre/post gene therapy","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal biochemical methods in primary patient cells with mechanistic rescue by gene therapy","pmids":["18218852"],"is_preprint":false},{"year":2009,"finding":"ADA deficiency causes a specific bone phenotype in mice characterized by an imbalanced RANKL/osteoprotegerin axis (decreased osteoclastogenesis) and intrinsic osteoblast dysfunction with low bone formation; ADA-deficient osteoblasts showed altered transcriptional profile and growth reduction in vitro, and the bone marrow microenvironment had reduced capacity to support hematopoiesis; enzyme replacement, bone marrow transplantation, or gene therapy fully rescued these defects.","method":"Mouse knockout model, bone structural analysis, in vitro osteoblast assays, RANKL/OPG measurement, hematopoietic support assay, rescue experiments (ERT/BMT/GT)","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in mouse model with mechanistic pathway identification and therapeutic rescue","pmids":["19633200"],"is_preprint":false},{"year":2010,"finding":"ADA2 is secreted by monocytes undergoing differentiation into macrophages or dendritic cells and binds to cell surfaces via proteoglycans and adenosine receptors; ADA2 (but not ADA1) induces T cell-dependent differentiation of monocytes into macrophages and stimulates macrophage proliferation; both ADA1 and ADA2 increase proliferation of monocyte-activated CD4+ T cells independently of their catalytic deaminase activity.","method":"Cell differentiation assays, surface binding assays, proteoglycan competition, receptor blocking, T cell proliferation assays","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 — multiple binding and functional assays distinguishing catalytic vs. non-catalytic roles; ADA2-specific functions established with mechanistic controls","pmids":["20453107"],"is_preprint":false},{"year":2013,"finding":"In neonatal blood, soluble ADA1 (not ADA2) is the enzyme responsible for catabolizing extracellular adenosine to inosine; neonatal plasma has substantially lower ADA activity than adult plasma, resulting in elevated extracellular adenosine concentrations in newborns; selective 5'-NT inhibition enhanced TLR-mediated TNF-α production in neonatal blood, confirming functional relevance of the adenosine-generating/catabolizing enzyme balance.","method":"Enzyme activity assays (ADA isoform-specific), plasma fractionation, pharmacological inhibition of 5'-NT, TLR stimulation/cytokine measurement in whole blood, infant cohort samples","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple biochemical and functional assays with isoform specificity established, validated in patient cohorts","pmids":["23897810"],"is_preprint":false},{"year":2013,"finding":"ADA acts as a natural antagonist for DPP4-mediated entry of MERS-CoV; ADA competed with MERS-CoV for DPP4 binding, and site-directed mutagenesis of ferret DPP4 residues identified the functional human DPP4 virus-binding site, which overlaps with the ADA-binding site.","method":"Site-directed mutagenesis, viral entry competition assay, receptor binding assays","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis combined with functional competition assay defining the shared binding site","pmids":["24257613"],"is_preprint":false},{"year":2015,"finding":"ADA1-expressing HEK293 cells (but not ADA2-expressing cells) extensively metabolize cordycepin by deamination, with Km of 54.9 μmol/L and Vmax of 45.8 nmol/min/mg protein; naringin strongly inhibits ADA1-mediated cordycepin deamination (Ki ~58.8 μmol/L in mouse erythrocytes), demonstrating ADA1 is the primary isoform responsible for cordycepin metabolism.","method":"Isoform-specific overexpression in HEK293 cells, enzyme kinetics, inhibition assays (Ki determination), cytotoxicity assay","journal":"Pharmacology research & perspectives","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with isoform-specific expression and kinetic characterization","pmids":["26038697"],"is_preprint":false},{"year":2016,"finding":"ADA1 and ADA2 bind to different subsets of immune cells: ADA2 binds to neutrophils, monocytes, NK cells, and B cells that do not express CD26 (the ADA1 receptor), and specifically to CD39+ regulatory T cells lacking CD26; ADA1 binds CD16- monocytes while CD16+ monocytes preferentially bind ADA2; ADA2-deficient patients show dramatic reduction in lymphocyte subsets and increased plasma TNF-α.","method":"Flow cytometry with isoform-specific binding assays, analysis of ADA2-deficient patient blood samples, cytokine measurement","journal":"Cellular and molecular life sciences","confidence":"High","confidence_rationale":"Tier 2 — systematic flow cytometry binding analysis across immune cell subsets with patient validation","pmids":["27663683"],"is_preprint":false},{"year":2017,"finding":"ADA deficiency in mice and patients causes neurological and behavioral abnormalities including motor dysfunction, EEG alterations, sensorineural hearing loss, and white matter alterations; ADA-deficient mice showed anxiety-like behavior coinciding with metabolic alterations and aberrant adenosine receptor signaling; PEG-ADA treatment corrected metabolic adenosine-based alterations but not cellular and signaling defects, indicating an intrinsic neurological component beyond peripheral adenosine levels.","method":"Mouse behavioral assays, EEG, MRI, metabolic/molecular analysis, adenosine receptor signaling assays, PEG-ADA treatment comparison","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in mouse and patient cohorts establishing intrinsic neurological role of ADA metabolism","pmids":["28074903"],"is_preprint":false},{"year":2005,"finding":"A functional genetic variant of ADA (G22A polymorphism, Asp8Asn), which reduces ADA enzyme activity, specifically enhances deep sleep and slow-wave activity (SWA) during sleep in humans, indicating ADA-mediated adenosine metabolism directly regulates sleep homeostasis.","method":"Human genetic study, polysomnography/EEG measurement of sleep parameters, comparison with A2A receptor polymorphism","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genotype-phenotype study with specific EEG/sleep readout, isoform-specific effect confirmed by comparison with different adenosine pathway variant","pmids":["16221767"],"is_preprint":false},{"year":1992,"finding":"Retroviral transfer of the ADA gene into ADA-deficient peripheral blood T lymphocytes restored ADA enzyme activity and reconstituted specific immune functions including proliferative capacity, alloreactive and antigen-specific responses in vivo in BNX immunodeficient mice, demonstrating that ADA enzymatic activity is required for T lymphocyte survival and immune function.","method":"Retroviral gene transfer, enzyme activity assay, in vivo T cell reconstitution in immunodeficient mice, TCR analysis, antigen-specific response assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — functional rescue by gene restoration with multiple immune function readouts","pmids":["1325209"],"is_preprint":false},{"year":2024,"finding":"Engineering CAR T cells to co-express membrane-bound CD26 and cytoplasmic ADA1 enables autocrine secretion of ADA1 upon CD3/CD26 stimulation; ADA1 converts adenosine to inosine which serves as alternative fuel, improving CAR T cell migration, resistance to TGF-β1 suppression, and anti-tumor activity in hepatocellular carcinoma and non-small cell lung cancer mouse models; fusion of ADA1 with anti-CD3 scFv further boosted inosine production.","method":"CAR T cell engineering, in vitro migration and suppression assays, mouse tumor models (HCC and NSCLC), ADA1 enzymatic activity assays","journal":"Cell reports. Medicine","confidence":"High","confidence_rationale":"Tier 2 — mechanistic engineering study with in vitro and in vivo functional validation across multiple tumor models","pmids":["38688275"],"is_preprint":false},{"year":2020,"finding":"Human subcutaneous fibroblasts have very low endogenous ADA activity; exogenous ADA addition converts adenosine to inosine which acts through A3 receptors to decrease fibroblast growth and collagen production, opposing the pro-collagen effects of adenosine acting via A2A receptors, demonstrating that ADA-expressing inflammatory cells (third-party ADA providers) can regulate dermal remodeling by controlling the adenosine/inosine balance.","method":"Cell culture, enzyme activity assays, receptor agonist/antagonist pharmacology, collagen production assay, proliferation assay","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological dissection of ADA enzymatic role in fibroblast biology using receptor-specific antagonists","pmids":["32156055"],"is_preprint":false}],"current_model":"Human ADA1 (adenosine deaminase 1) is a purine metabolism enzyme that deaminates adenosine and 2'-deoxyadenosine to inosine and 2'-deoxyinosine; it is encoded by a 12-exon gene on chromosome 20q13.2 with a TATA-less, G/C-rich SP1-dependent promoter, and functions both intracellularly (where its deficiency causes toxic accumulation of deoxyadenosine substrates that impair ZAP-70/ERK/NF-κB T cell signaling) and as a cell-surface ectoenzyme anchored via CD26/DPP4 (and A1/A2B adenosine receptors) where it regulates extracellular adenosine levels, provides non-enzymatic costimulatory signals at the immunological synapse, and controls sleep homeostasis; a second isoform, ADA2, is secreted by monocytes, binds different immune cell subsets via proteoglycans and adenosine receptors, and promotes macrophage differentiation and proliferation independently of its catalytic activity."},"narrative":{"teleology":[{"year":1984,"claim":"Establishing the chromosomal locus and nature of ADA-SCID mutations resolved whether deficiency arose from transcriptional silencing or protein-level dysfunction, showing that SCID cells produce ADA mRNA encoding a structurally altered, catalytically inactive protein.","evidence":"Northern blot, in vitro translation, and immunoprecipitation of SCID-derived ADA mRNA products; somatic cell hybridization mapped ADA to 20q13.2","pmids":["6198631","6370091"],"confidence":"High","gaps":["Specific point mutations causing misfolding were not identified","No structural basis for loss of immunoreactivity"]},{"year":1986,"claim":"Complete gene characterization revealed an unusual TATA-less, GC-rich promoter architecture with SP1-dependent regulation, defining the transcriptional control elements of ADA and enabling future gene therapy vector design.","evidence":"Cosmid/phage clone sequencing and functional promoter assays identified 12 exons over ~32–37 kb with six SP1-binding motifs","pmids":["3839456","3028473"],"confidence":"High","gaps":["Cell-type-specific enhancer elements not characterized","Regulation of tissue-variable ADA expression not explained by promoter alone"]},{"year":1993,"claim":"Identification of CD26/DPP4 as the surface anchor for ADA transformed understanding of ADA from a purely intracellular metabolic enzyme to a cell-surface ectoenzyme, opening the field of ADA-mediated cell signaling.","evidence":"Amino acid sequencing of the 43-kDa CD26-associated protein, reciprocal immunoprecipitation, and in vitro binding assays","pmids":["8101391"],"confidence":"High","gaps":["Stoichiometry and affinity of the ADA–CD26 complex not quantified","Whether ADA binding modulates CD26 peptidase activity was unknown"]},{"year":1997,"claim":"Extension of ADA surface-binding partners beyond CD26 to include A1 adenosine receptors broadened the ectoenzyme concept to include neuromodulatory contexts, suggesting ADA regulates adenosine tone at neuronal surfaces.","evidence":"Cell surface binding studies, signal transduction assays, and immunohistochemistry across neural tissues","pmids":["9247966"],"confidence":"Medium","gaps":["Direct in vivo demonstration of ADA–A1R complex function in neurons was lacking","Relative contribution of A1R vs. CD26 anchoring in different tissues unclear"]},{"year":2005,"claim":"Two concurrent breakthroughs established non-enzymatic functions and physiological endpoints: ADA at the immunological synapse provides catalysis-independent costimulation amplifying cytokine production, while a human ADA polymorphism (Asp8Asn) that reduces enzymatic activity directly modulates sleep depth.","evidence":"Autologous T cell/DC cocultures with catalytically inactive ADA controls showed 3–34-fold cytokine enhancement; genotype-phenotype study with polysomnography linked G22A to enhanced slow-wave activity","pmids":["15983379","16221767"],"confidence":"High","gaps":["Identity of the dendritic-cell ADA-anchoring protein at the synapse unresolved","Mechanism linking reduced ADA activity to increased slow-wave sleep not defined at the molecular level"]},{"year":2008,"claim":"Molecular dissection of ADA-SCID T cells pinpointed the signaling defects—impaired ZAP-70 phosphorylation, Ca²⁺ flux, ERK1/2, CREB, and NF-κB—and showed that deoxyadenosine additionally suppresses T cells through aberrant A2A receptor/PKA signaling; gene therapy rescued all these biochemical defects.","evidence":"Phospho-flow, Ca²⁺ flux, transcription factor assays, and apoptosis assays in ADA-SCID patient T cells pre- and post-gene therapy","pmids":["18218852"],"confidence":"High","gaps":["Relative contribution of intracellular dATP accumulation vs. extracellular deoxyadenosine signaling not fully deconvoluted","Threshold of ADA restoration needed for full signaling recovery not defined"]},{"year":2009,"claim":"Discovery of a bone phenotype in ADA-deficient mice—imbalanced RANKL/OPG axis and intrinsic osteoblast dysfunction—expanded the disease spectrum beyond immunodeficiency and showed the bone marrow microenvironment depends on purine homeostasis for hematopoietic support.","evidence":"ADA-knockout mouse bone analysis, in vitro osteoblast assays, RANKL/OPG quantification, rescue by ERT/BMT/gene therapy","pmids":["19633200"],"confidence":"High","gaps":["Specific metabolites (adenosine vs. deoxyadenosine) responsible for osteoblast dysfunction not distinguished","Human bone phenotype not systematically characterized"]},{"year":2013,"claim":"Two advances clarified isoform-specific biology: ADA1 (not ADA2) is the dominant extracellular adenosine-catabolizing enzyme in plasma, and ADA competes with MERS-CoV for the DPP4/CD26 binding site, revealing an unexpected antiviral role.","evidence":"Isoform-specific enzyme assays in fractionated neonatal/adult plasma; site-directed mutagenesis and viral entry competition assays for MERS-CoV–DPP4 interaction","pmids":["23897810","24257613"],"confidence":"High","gaps":["In vivo relevance of ADA–DPP4 competition for MERS-CoV infection not tested in animal models","Whether low neonatal ADA1 activity contributes to neonatal infection susceptibility not established"]},{"year":2016,"claim":"Systematic mapping of ADA1 and ADA2 binding to immune cell subsets revealed complementary distribution: ADA1 binds CD26⁺ cells (including CD16⁻ monocytes) while ADA2 binds CD26⁻ cells (neutrophils, NK cells, B cells, CD39⁺ Tregs), establishing non-redundant immunomodulatory roles for each isoform.","evidence":"Flow cytometry with isoform-specific binding, validated in ADA2-deficient patient samples showing lymphocyte depletion and elevated TNF-α","pmids":["27663683"],"confidence":"High","gaps":["Molecular identity of the ADA2 surface receptor on CD26⁻ cells not fully defined beyond proteoglycans/adenosine receptors","Functional consequences of ADA2 binding to specific subsets (e.g., Tregs) not mechanistically resolved"]},{"year":2017,"claim":"Neurological abnormalities in ADA-deficient mice and patients—motor dysfunction, EEG alterations, hearing loss, white matter changes—persist after enzyme replacement, revealing an intrinsic CNS component of ADA deficiency not correctable by peripheral adenosine normalization.","evidence":"Behavioral, EEG, MRI, and molecular analyses in ADA-knockout mice with PEG-ADA treatment, cross-referenced with patient neurological data","pmids":["28074903"],"confidence":"High","gaps":["Whether neurological defects arise during a critical developmental window or are ongoing not resolved","Blood-brain barrier penetration of PEG-ADA not measured"]},{"year":2024,"claim":"Engineered co-expression of ADA1 and CD26 in CAR T cells demonstrated that ADA1-generated inosine serves as alternative fuel and confers resistance to adenosine-mediated and TGF-β1-mediated immunosuppression in the tumor microenvironment, translating decades of basic ADA biology into therapeutic application.","evidence":"CAR T cell engineering with membrane CD26 and cytoplasmic ADA1, validated by migration assays, suppression resistance, and anti-tumor efficacy in HCC and NSCLC mouse models","pmids":["38688275"],"confidence":"High","gaps":["Long-term safety of constitutive ADA1 overexpression in T cells not assessed","Whether inosine fuel utilization or adenosine depletion is the dominant mechanism in vivo not deconvoluted"]},{"year":null,"claim":"Key unresolved questions include the identity of the dendritic-cell ADA-anchoring protein at the immunological synapse, the molecular mechanism by which ADA activity modulates sleep homeostasis, the developmental timing of irreversible CNS damage in ADA deficiency, and the structural basis for ADA1 vs. ADA2 receptor selectivity.","evidence":"Open questions synthesized from gaps across the literature","pmids":[],"confidence":"Low","gaps":["No structural model of the ADA–A1R or ADA2–proteoglycan complex exists","In vivo isoform-specific roles in different tissue niches remain poorly quantified","Whether ADA1 enzymatic and costimulatory functions are separable in a therapeutic context is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[8,11,13,18,19]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,10,12]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4,5,6,7,14]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,8,18]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[10,11]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8,11,13,18,19]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,8,10,14,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,6,8,16]}],"complexes":[],"partners":["DPP4","ADORA1","ADORA2A","ADORA2B","ADORA3"],"other_free_text":[]},"mechanistic_narrative":"ADA (adenosine deaminase 1) is a purine-metabolizing enzyme that catalyzes the irreversible deamination of adenosine and 2′-deoxyadenosine to inosine and 2′-deoxyinosine, functioning both intracellularly to prevent toxic substrate accumulation and extracellularly as an ectoenzyme anchored to the cell surface via CD26/DPP4 and adenosine receptors, where it regulates local adenosine concentrations and provides catalysis-independent costimulatory signals at the immunological synapse [PMID:8101391, PMID:15983379, PMID:23897810]. ADA deficiency causes severe combined immunodeficiency (SCID) through impaired T-cell receptor signaling—specifically reduced ZAP-70 phosphorylation, Ca²⁺ flux, ERK1/2 activation, and NF-κB transcriptional activity—as well as skeletal defects from osteoblast dysfunction and neurological abnormalities linked to aberrant adenosine receptor signaling, defects that are correctable by gene therapy or enzyme replacement [PMID:18218852, PMID:19633200, PMID:28074903]. A common functional polymorphism (G22A/Asp8Asn) that reduces ADA activity enhances slow-wave sleep in humans, establishing ADA-mediated adenosine catabolism as a direct regulator of sleep homeostasis [PMID:16221767]. ADA also competitively inhibits MERS-CoV binding to its receptor DPP4/CD26, and its inosine product can serve as an alternative metabolic fuel for T cells in immunosuppressive tumor microenvironments [PMID:24257613, PMID:38688275]."},"prefetch_data":{"uniprot":{"accession":"P00813","full_name":"Adenosine deaminase","aliases":["Adenosine aminohydrolase"],"length_aa":363,"mass_kda":40.8,"function":"Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine (PubMed:16670267, PubMed:23193172, PubMed:26166670, PubMed:8452534, PubMed:9361033). Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4 (PubMed:20959412). Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion (PubMed:11772392). Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion (By similarity). Enhances CD4+ T-cell differentiation and proliferation (PubMed:20959412). Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change (PubMed:23193172). Stimulates plasminogen activation (PubMed:15016824). Plays a role in male fertility (PubMed:21919946, PubMed:26166670). Plays a protective role in early postimplantation embryonic development (By similarity). Also responsible for the deamination of cordycepin (3'-deoxyadenosine), a fungal natural product that shows antitumor, antibacterial, antifungal, antivirus, and immune regulation properties (PubMed:26038697)","subcellular_location":"Cell membrane; Cell junction; Cytoplasmic vesicle lumen; Cytoplasm; Lysosome","url":"https://www.uniprot.org/uniprotkb/P00813/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADA","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADA","total_profiled":1310},"omim":[{"mim_id":"619952","title":"TRANSMEMBRANE PROTEIN 63B; TMEM63B","url":"https://www.omim.org/entry/619952"},{"mim_id":"619346","title":"ADENOSINE DEAMINASE-LIKE PROTEIN; ADAL","url":"https://www.omim.org/entry/619346"},{"mim_id":"618310","title":"DIAMOND-BLACKFAN ANEMIA 18; DBA18","url":"https://www.omim.org/entry/618310"},{"mim_id":"615688","title":"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME; VAIHS","url":"https://www.omim.org/entry/615688"},{"mim_id":"613938","title":"PARASOMNIA, SLEEPWALKING TYPE; PSMNSW","url":"https://www.omim.org/entry/613938"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":454.0},{"tissue":"lymphoid tissue","ntpm":228.3}],"url":"https://www.proteinatlas.org/search/ADA"},"hgnc":{"alias_symbol":["ADA1"],"prev_symbol":[]},"alphafold":{"accession":"P00813","domains":[{"cath_id":"3.20.20.140","chopping":"10-354","consensus_level":"high","plddt":98.2289,"start":10,"end":354}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P00813","model_url":"https://alphafold.ebi.ac.uk/files/AF-P00813-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P00813-F1-predicted_aligned_error_v6.png","plddt_mean":96.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADA","jax_strain_url":"https://www.jax.org/strain/search?query=ADA"},"sequence":{"accession":"P00813","fasta_url":"https://rest.uniprot.org/uniprotkb/P00813.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P00813/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P00813"}},"corpus_meta":[{"pmid":"30291106","id":"PMC_30291106","title":"Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2018","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/30291106","citation_count":1913,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36148880","id":"PMC_36148880","title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2022","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/36148880","citation_count":1243,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9224714","id":"PMC_9224714","title":"Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complex.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9224714","citation_count":923,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12089448","id":"PMC_12089448","title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.","date":"2002","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12089448","citation_count":871,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31857443","id":"PMC_31857443","title":"2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2019","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/31857443","citation_count":848,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25249672","id":"PMC_25249672","title":"Diabetic kidney disease: a report from an ADA Consensus Conference.","date":"2014","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/25249672","citation_count":841,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30288571","id":"PMC_30288571","title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2018","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/30288571","citation_count":799,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36151309","id":"PMC_36151309","title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2022","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/36151309","citation_count":659,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7570000","id":"PMC_7570000","title":"Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7570000","citation_count":580,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36189689","id":"PMC_36189689","title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).","date":"2022","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/36189689","citation_count":554,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25257325","id":"PMC_25257325","title":"Diabetic kidney disease: a report from an ADA Consensus Conference.","date":"2014","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/25257325","citation_count":440,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31853556","id":"PMC_31853556","title":"2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2020","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/31853556","citation_count":345,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9335585","id":"PMC_9335585","title":"Essential functional interactions of SAGA, a Saccharomyces cerevisiae complex of Spt, Ada, and Gcn5 proteins, with the Snf/Swi and Srb/mediator complexes.","date":"1997","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9335585","citation_count":268,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9662367","id":"PMC_9662367","title":"T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.","date":"1998","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9662367","citation_count":250,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36202661","id":"PMC_36202661","title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).","date":"2022","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/36202661","citation_count":201,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17671653","id":"PMC_17671653","title":"Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17671653","citation_count":198,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9343382","id":"PMC_9343382","title":"Role for ADA/GCN5 products in antagonizing chromatin-mediated transcriptional repression.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9343382","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28396566","id":"PMC_28396566","title":"Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products.","date":"2017","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28396566","citation_count":184,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19638621","id":"PMC_19638621","title":"How I treat ADA deficiency.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19638621","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2987862","id":"PMC_2987862","title":"Methyl phosphotriesters in alkylated DNA are repaired by the Ada regulatory protein of E. coli.","date":"1985","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2987862","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9756893","id":"PMC_9756893","title":"Tra1p is a component of the yeast Ada.Spt transcriptional regulatory complexes.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9756893","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27663683","id":"PMC_27663683","title":"Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/27663683","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9154821","id":"PMC_9154821","title":"ADA1, a novel component of the ADA/GCN5 complex, has broader effects than GCN5, ADA2, or ADA3.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9154821","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3162236","id":"PMC_3162236","title":"Functional domains and methyl acceptor sites of the Escherichia coli ada protein.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3162236","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2081198","id":"PMC_2081198","title":"The ADA human gene therapy clinical protocol.","date":"1990","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/2081198","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8649430","id":"PMC_8649430","title":"ADA5/SPT20 links the ADA and SPT genes, which are involved in yeast transcription.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8649430","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30423394","id":"PMC_30423394","title":"Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","date":"2018","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30423394","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28842866","id":"PMC_28842866","title":"Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.","date":"2017","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28842866","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23897810","id":"PMC_23897810","title":"Soluble ecto-5'-nucleotidase (5'-NT), alkaline phosphatase, and adenosine deaminase (ADA1) activities in neonatal blood favor elevated extracellular adenosine.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23897810","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28847159","id":"PMC_28847159","title":"Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.","date":"2017","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28847159","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6749819","id":"PMC_6749819","title":"O6-methylguanine-DNA methyltransferase in wild-type and ada mutants of Escherichia coli.","date":"1982","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/6749819","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16209950","id":"PMC_16209950","title":"A methylation-dependent electrostatic switch controls DNA repair and transcriptional activation by E. coli ada.","date":"2005","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16209950","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19633200","id":"PMC_19633200","title":"ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19633200","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9154805","id":"PMC_9154805","title":"Role of the Ada adaptor complex in gene activation by the glucocorticoid receptor.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9154805","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18218852","id":"PMC_18218852","title":"Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18218852","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3047400","id":"PMC_3047400","title":"Functional sites of the Ada regulatory protein of Escherichia coli. Analysis by amino acid substitutions.","date":"1988","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3047400","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2120677","id":"PMC_2120677","title":"Bacillus subtilis ada operon encodes two DNA alkyltransferases.","date":"1990","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2120677","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23796864","id":"PMC_23796864","title":"Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy.","date":"2013","source":"The Journal of infection","url":"https://pubmed.ncbi.nlm.nih.gov/23796864","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1581309","id":"PMC_1581309","title":"Zinc binding by the methylation signaling domain of the Escherichia coli Ada protein.","date":"1992","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1581309","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26038697","id":"PMC_26038697","title":"Inhibition of adenosine deaminase (ADA)-mediated metabolism of cordycepin by natural substances.","date":"2015","source":"Pharmacology research & perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/26038697","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25713136","id":"PMC_25713136","title":"Conformational flexibility and subunit arrangement of the modular yeast Spt-Ada-Gcn5 acetyltransferase complex.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25713136","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3323828","id":"PMC_3323828","title":"DNA base changes induced following in vivo exposure of unadapted, adapted or ada- Escherichia coli to N-methyl-N'-nitro-N-nitrosoguanidine.","date":"1987","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/3323828","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26468280","id":"PMC_26468280","title":"Subunits of ADA-two-A-containing (ATAC) or Spt-Ada-Gcn5-acetyltrasferase (SAGA) Coactivator Complexes Enhance the Acetyltransferase Activity of GCN5.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26468280","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35671392","id":"PMC_35671392","title":"Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35671392","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2254928","id":"PMC_2254928","title":"Positive and negative regulation of transcription by a cleavage product of Ada protein.","date":"1990","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2254928","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6198631","id":"PMC_6198631","title":"Adenosine deaminase (ADA) deficiency in cells derived from humans with severe combined immunodeficiency is due to an aberration of the ADA protein.","date":"1984","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/6198631","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7749407","id":"PMC_7749407","title":"PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency.","date":"1995","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/7749407","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35420773","id":"PMC_35420773","title":"A-DA'D-A Structured Organic Phototheranostics for NIR-II Fluorescence/Photoacoustic Imaging-Guided Photothermal and Photodynamic Synergistic Therapy.","date":"2022","source":"ACS applied materials & interfaces","url":"https://pubmed.ncbi.nlm.nih.gov/35420773","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3139888","id":"PMC_3139888","title":"Expression of the ada gene of Escherichia coli in response to alkylating agents. Identification of transcriptional regulatory elements.","date":"1988","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3139888","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28074903","id":"PMC_28074903","title":"Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28074903","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3929077","id":"PMC_3929077","title":"Regulation of expression of the cloned ada gene in Escherichia coli.","date":"1985","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/3929077","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1325209","id":"PMC_1325209","title":"Transfer of the ADA gene into human ADA-deficient T lymphocytes reconstitutes specific immune functions.","date":"1992","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1325209","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7937881","id":"PMC_7937881","title":"The Ada protein acts as both a positive and a negative modulator of Escherichia coli's response to methylating agents.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7937881","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28194615","id":"PMC_28194615","title":"How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).","date":"2017","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28194615","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20007317","id":"PMC_20007317","title":"Structural basis for the interaction between yeast Spt-Ada-Gcn5 acetyltransferase (SAGA) complex components Sgf11 and Sus1.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20007317","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27034966","id":"PMC_27034966","title":"Development of Immunocapture-LC/MS Assay for Simultaneous ADA Isotyping and Semiquantitation.","date":"2016","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/27034966","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24810496","id":"PMC_24810496","title":"Ada response - a strategy for repair of alkylated DNA in bacteria.","date":"2014","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24810496","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8376346","id":"PMC_8376346","title":"Bacillus subtilis alkA gene encoding inducible 3-methyladenine DNA glycosylase is adjacent to the ada operon.","date":"1993","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/8376346","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24076575","id":"PMC_24076575","title":"The inclusion of ADA-SCID in expanded newborn screening by tandem mass spectrometry.","date":"2013","source":"Journal of pharmaceutical and biomedical analysis","url":"https://pubmed.ncbi.nlm.nih.gov/24076575","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35663977","id":"PMC_35663977","title":"Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35663977","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29744787","id":"PMC_29744787","title":"ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.","date":"2018","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29744787","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2530449","id":"PMC_2530449","title":"Enhanced O6-methylguanine-DNA methyltransferase activity in transgenic mice containing an integrated E. coli ada repair gene.","date":"1989","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/2530449","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15824526","id":"PMC_15824526","title":"Tuberculous effusion: ADA activity correlates with CD4+ cell numbers in the fluid and the pleura.","date":"2005","source":"Respiration; international review of thoracic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/15824526","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6370091","id":"PMC_6370091","title":"Confirmation of the regional localization of the genes for human acid alpha-glucosidase (GAA) and adenosine deaminase (ADA) by somatic cell hybridization.","date":"1984","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6370091","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38185066","id":"PMC_38185066","title":"A new andrographolide derivative ADA targeting SIRT3-FOXO3a signaling mitigates cognitive impairment by activating mitophagy and inhibiting neuroinflammation in Apoe4 mice.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38185066","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28351939","id":"PMC_28351939","title":"Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28351939","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38688902","id":"PMC_38688902","title":"A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38688902","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9383376","id":"PMC_9383376","title":"Metal-coordination sphere in the methylated Ada protein-DNA co-complex.","date":"1994","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/9383376","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36309141","id":"PMC_36309141","title":"Zinc normalizes hepatic lipid handling via modulation of ADA/XO/UA pathway and caspase 3 signaling in highly active antiretroviral therapy-treated Wistar rats.","date":"2022","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/36309141","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2843522","id":"PMC_2843522","title":"Activation of Ada protein as a transcriptional regulator by direct alkylation with methylating agents.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2843522","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21624848","id":"PMC_21624848","title":"Novel mutations in RAG1/2 and ADA genes in Israeli patients presenting with T-B-SCID or Omenn syndrome.","date":"2011","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/21624848","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32880085","id":"PMC_32880085","title":"Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry.","date":"2020","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32880085","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26263547","id":"PMC_26263547","title":"Spt-Ada-Gcn5-Acetyltransferase (SAGA) Complex in Plants: Genome Wide Identification, Evolutionary Conservation and Functional Determination.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26263547","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21570366","id":"PMC_21570366","title":"The ada operon of Mycobacterium tuberculosis encodes two DNA methyltransferases for inducible repair of DNA alkylation damage.","date":"2011","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/21570366","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3526284","id":"PMC_3526284","title":"Mutant Escherichia coli Ada proteins simultaneously defective in the repair of O6-methylguanine and in gene activation.","date":"1986","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/3526284","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17287605","id":"PMC_17287605","title":"ADA*2 allele of the adenosine deaminase gene may protect against coronary artery disease.","date":"2007","source":"Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/17287605","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11284682","id":"PMC_11284682","title":"Structural basis for the functional switch of the E. coli Ada protein.","date":"2001","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11284682","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12435054","id":"PMC_12435054","title":"Advances in gene therapy for ADA-deficient SCID.","date":"2002","source":"Current opinion in molecular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/12435054","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3547105","id":"PMC_3547105","title":"Proteolytic processing of the Ada protein that repairs DNA O6-methylguanine residues in E. coli.","date":"1987","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/3547105","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8468304","id":"PMC_8468304","title":"The Ada protein is a class I transcription factor of Escherichia coli.","date":"1993","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/8468304","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38688275","id":"PMC_38688275","title":"Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38688275","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2054779","id":"PMC_2054779","title":"Enhanced repair of O6-methylguanine DNA adducts in the liver of transgenic mice expressing the ada gene.","date":"1991","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/2054779","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30093511","id":"PMC_30093511","title":"Evaluation of ADA HbA1c criteria in the diagnosis of pre-diabetes and diabetes in a population of Chinese adolescents and young adults at high risk for diabetes: a cross-sectional study.","date":"2018","source":"BMJ open","url":"https://pubmed.ncbi.nlm.nih.gov/30093511","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3141384","id":"PMC_3141384","title":"Alteration of the carboxyl-terminal domain of Ada protein influences its inducibility, specificity, and strength as a transcriptional activator.","date":"1988","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/3141384","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24509845","id":"PMC_24509845","title":"DNA binding by Sgf11 protein affects histone H2B deubiquitination by Spt-Ada-Gcn5-acetyltransferase (SAGA).","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24509845","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38029911","id":"PMC_38029911","title":"3D bioprinting of multifunctional alginate dialdehyde (ADA)-gelatin (GEL) (ADA-GEL) hydrogels incorporating ferulic acid.","date":"2023","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38029911","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17852820","id":"PMC_17852820","title":"Pleural fluid ADA, IgA-ELISA and PCR sensitivities for the diagnosis of pleural tuberculosis.","date":"2007","source":"Scandinavian journal of clinical and laboratory investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17852820","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26376800","id":"PMC_26376800","title":"Diagnosis, Treatment and Long-Term Follow Up of Patients with ADA Deficiency: a Single-Center Experience.","date":"2015","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26376800","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10036850","id":"PMC_10036850","title":"The dental team and latex hypersensitivity. ADA Council on Scientific Affairs.","date":"1999","source":"Journal of the American Dental Association (1939)","url":"https://pubmed.ncbi.nlm.nih.gov/10036850","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29625577","id":"PMC_29625577","title":"Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID.","date":"2018","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/29625577","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3058696","id":"PMC_3058696","title":"Proteolytic cleavage of Ada protein that carries methyltransferase and transcriptional regulator activities.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3058696","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2052012","id":"PMC_2052012","title":"Characterization of O6-methylguanine-DNA methyltransferase in transgenic mice introduced with the E. coli ada gene.","date":"1991","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/2052012","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31989577","id":"PMC_31989577","title":"Comparison of elapegademase and pegademase in ADA-deficient patients and mice.","date":"2020","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31989577","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10445834","id":"PMC_10445834","title":"Comparison of ADA and WHO screening methods for diabetes mellitus in obese patients. American Diabetes Association.","date":"1999","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/10445834","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17340203","id":"PMC_17340203","title":"The G22A polymorphism of the ADA gene and susceptibility to autism spectrum disorders.","date":"2007","source":"Journal of autism and developmental disorders","url":"https://pubmed.ncbi.nlm.nih.gov/17340203","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8148053","id":"PMC_8148053","title":"Influence of DNA repair by ada and ogt alkyltransferases on the mutational specificity of alkylating agents.","date":"1994","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/8148053","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34023075","id":"PMC_34023075","title":"Comparative genomics of the ADA clade within the Nostocales.","date":"2021","source":"Harmful algae","url":"https://pubmed.ncbi.nlm.nih.gov/34023075","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32156055","id":"PMC_32156055","title":"Opposing Effects of Adenosine and Inosine in Human Subcutaneous Fibroblasts May Be Regulated by Third Party ADA Cell Providers.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32156055","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32043202","id":"PMC_32043202","title":"The sensitive detection of ATP and ADA based on turn-on fluorescent copper/silver nanoclusters.","date":"2020","source":"Analytical and bioanalytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32043202","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27300446","id":"PMC_27300446","title":"Pleural Fluid Adenosine Deaminase (ADA) Predicts Survival in Patients with Malignant Pleural Effusion.","date":"2016","source":"Lung","url":"https://pubmed.ncbi.nlm.nih.gov/27300446","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23128233","id":"PMC_23128233","title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23128233","citation_count":3725,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7570001","id":"PMC_7570001","title":"T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7570001","citation_count":1008,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8101391","id":"PMC_8101391","title":"Direct association of adenosine deaminase with a T cell activation antigen, CD26.","date":"1993","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8101391","citation_count":467,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9674425","id":"PMC_9674425","title":"Histone-like TAFs within the PCAF histone acetylase complex.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9674425","citation_count":462,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3839456","id":"PMC_3839456","title":"Adenosine deaminase: characterization and expression of a gene with a remarkable promoter.","date":"1985","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/3839456","citation_count":303,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28319113","id":"PMC_28319113","title":"Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions.","date":"2017","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/28319113","citation_count":266,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9247966","id":"PMC_9247966","title":"Cell surface adenosine deaminase: much more than an ectoenzyme.","date":"1997","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/9247966","citation_count":208,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15983379","id":"PMC_15983379","title":"CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15983379","citation_count":206,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20453107","id":"PMC_20453107","title":"Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages.","date":"2010","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/20453107","citation_count":190,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16221767","id":"PMC_16221767","title":"A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16221767","citation_count":171,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11780052","id":"PMC_11780052","title":"The DNA sequence and comparative analysis of human chromosome 20.","date":"2001","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11780052","citation_count":168,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10506947","id":"PMC_10506947","title":"Enzymes involved in purine metabolism--a review of histochemical localization and functional implications.","date":"1999","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/10506947","citation_count":152,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16670267","id":"PMC_16670267","title":"Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16670267","citation_count":145,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3028473","id":"PMC_3028473","title":"Complete sequence and structure of the gene for human adenosine deaminase.","date":"1986","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3028473","citation_count":141,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24257613","id":"PMC_24257613","title":"Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/24257613","citation_count":136,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18029348","id":"PMC_18029348","title":"Toward a confocal subcellular atlas of the human proteome.","date":"2007","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/18029348","citation_count":114,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27453043","id":"PMC_27453043","title":"A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27453043","citation_count":113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19470168","id":"PMC_19470168","title":"NPAS2 and PER2 are linked to risk factors of the metabolic syndrome.","date":"2009","source":"Journal of circadian rhythms","url":"https://pubmed.ncbi.nlm.nih.gov/19470168","citation_count":112,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24722188","id":"PMC_24722188","title":"Protein interaction network of alternatively spliced isoforms from brain links genetic risk factors for autism.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24722188","citation_count":111,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9414266","id":"PMC_9414266","title":"Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9414266","citation_count":111,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47469,"output_tokens":4692,"usd":0.106394},"stage2":{"model":"claude-opus-4-6","input_tokens":8237,"output_tokens":2691,"usd":0.16269},"total_usd":0.593903,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":59436,"output_tokens":6355,"usd":0.136817},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":8617,"output_tokens":3290,"usd":0.188002}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"The E. coli Ada protein (39 kDa) repairs O6-methylguanine and O4-methylthymine residues in alkylated DNA by direct, irreversible transfer of the methyl group from the base to a cysteine residue within the protein itself; it also repairs one stereoisomer of methyl phosphotriester lesions via the same direct methyl-transfer mechanism, using a different cysteine residue as acceptor.\",\n      \"method\": \"In vitro methyltransferase assay with purified Ada protein; stereoisomer-selective repair demonstrated biochemically\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with purified protein, replicated across multiple studies\",\n      \"pmids\": [\"2987862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Ada protein comprises two stable functional domains linked by a ~10-amino-acid hinge: the N-terminal domain (with Cys-69 as the methyl acceptor for phosphotriester repair) and the C-terminal domain (with Cys-321 as the methyl acceptor for O6-methylguanine repair). Methylation of Cys-69 converts Ada into a transcriptional activator.\",\n      \"method\": \"Limited proteolysis mapping each domain's methyltransferase activity; identification of Cys-69 as the methylation site by post-translational modification analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — domain mapping by proteolysis plus in vitro methyltransferase assays; Cys-69 identified as activating methylation site\",\n      \"pmids\": [\"3162236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Site-directed mutagenesis of Ada confirmed that Cys-69 (N-terminal domain) is solely required for phosphotriester repair and transcriptional activation of both ada and alkA genes, while Cys-321 (C-terminal domain) is required for O6-methylguanine/O4-methylthymine repair. Replacement of Cys-69 abolishes transcriptional activation; replacement of Cys-321 increases constitutive ada transcription, indicating Cys-321 also modulates transcriptional regulation.\",\n      \"method\": \"Site-directed mutagenesis; in vitro and in vivo transcription assays; alkylation sensitivity assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — site-directed mutagenesis with in vitro and in vivo functional validation\",\n      \"pmids\": [\"3047400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Ada protein is directly activated as a transcriptional regulator through direct methylation by selective methylating agents (e.g., methyl methanesulfonate, methyl iodide) acting on the purified protein itself, independent of DNA-mediated methyl transfer, as demonstrated by in vitro transcription assays.\",\n      \"method\": \"Treatment of purified Ada protein with methylating agents followed by in vitro reconstituted ada transcription assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro assay with purified protein, single study\",\n      \"pmids\": [\"2843522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Deletions in the C-terminal domain of Ada produce derivatives that constitutively activate ada transcription or act as dominant inhibitors of ada induction while remaining inducible activators of alkA; this demonstrates the C-terminal domain modulates the inducibility, specificity, and strength of Ada as a transcriptional activator.\",\n      \"method\": \"Ordered 3′ deletion analysis of the ada gene; in vivo transcription reporter assays\",\n      \"journal\": \"Journal of bacteriology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion analysis with functional readout, single study\",\n      \"pmids\": [\"3141384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The ada promoter contains an eight-nucleotide regulatory sequence (Ada box: AAAGCGCA) located ~53 nt upstream of the transcription start site, which is required for methylated Ada protein to activate ada transcription. Methylated Ada facilitates RNA polymerase binding to the promoter in vitro.\",\n      \"method\": \"Random and site-directed mutagenesis of the ada promoter; deletion analyses; in vitro transcription reconstitution with methylated Ada\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — promoter mutagenesis combined with in vitro transcription reconstitution\",\n      \"pmids\": [\"3139888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Proteolytic cleavage of Ada by a cellular thiol protease generates a 20-kDa N-terminal fragment and a 19-kDa C-terminal fragment. The methylated 20-kDa fragment activates alkA transcription but occupies the ada promoter without activating it, acting as a repressor for ada transcription, thereby providing a mechanism for termination of the adaptive response.\",\n      \"method\": \"In vitro proteolysis; purification of cleavage products; in vitro and in vivo transcription assays; methyltransferase activity assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with purified fragments, confirmed in vivo\",\n      \"pmids\": [\"2254928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Proteolysis of Ada by a cellular thiol protease yields a 20-kDa N-terminal fragment (methylphosphotriester methyltransferase activity) and a 19-kDa C-terminal fragment (O6-methylguanine methyltransferase activity); neither fragment alone supports ada promoter transcription after methylation.\",\n      \"method\": \"Partial purification of the cellular Ada protease; SDS-PAGE and enzymatic activity assays of purified cleavage products\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified protease and substrates, activity assays with reconstituted fragments\",\n      \"pmids\": [\"3058696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The N-terminal domain of Ada contains a high-affinity single zinc-binding site, coordinated by four conserved cysteine residues (including Cys-69). The C-terminal domain is zinc-free. Zinc coordination is proposed to be essential for the methylation-dependent conformational switch that converts Ada from a non-sequence-specific to sequence-specific DNA-binding transcriptional activator.\",\n      \"method\": \"Metal-binding analysis of purified N-terminal and C-terminal Ada domains; biochemical characterization of zinc coordination\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical characterization with purified protein domains\",\n      \"pmids\": [\"1581309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Methylated Ada protein is a class I transcription factor: it binds upstream of the ada promoter (−62 to −31) and requires the C-terminal region of the RNA polymerase α subunit for transcription activation, as demonstrated by mutant RNA polymerases with C-terminal-deleted α subunits that are inactive in Ada-dependent activation.\",\n      \"method\": \"In vitro transcription with mutant RNA polymerases; DNA-binding assays\",\n      \"journal\": \"Journal of bacteriology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro transcription reconstitution with defined mutant components\",\n      \"pmids\": [\"8468304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Unmethylated Ada at physiologically relevant concentrations inhibits activation of ada transcription by methylated Ada (negative autoregulation), both in vitro and in vivo; this inhibition requires the C-terminal 67 amino acids of Ada. This negative modulation does not affect alkA transcription, demonstrating promoter-specific regulation.\",\n      \"method\": \"In vitro transcription assays; in vivo reporter assays; C-terminal deletion mutants of Ada\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro and in vivo concordant results with defined deletion mutants\",\n      \"pmids\": [\"7937881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"NMR analysis confirmed that S-Me-Cys69 (methylated Cys-69) remains coordinated to zinc in the transcriptionally active Ada-DNA complex; ligand exchange is not the mechanism underlying Ada's switch from DNA repair to transcriptional activator.\",\n      \"method\": \"13C-labeled methyl group on Cys-69; isotope-edited NMR; comparison of Zn- and Cd-substituted forms\",\n      \"journal\": \"Chemistry & biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structural analysis with isotopically labeled protein\",\n      \"pmids\": [\"9383376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"High-resolution NMR solution structure of the 10-kDa N-terminal Ada domain (N-Ada10) showed that methylation of Cys-69 induces a structural change that remodels a surface region (not including the transferred methyl group) to enhance promoter-specific DNA binding; EXAFS/XANES confirmed the zinc-thiolate center is maintained after methylation, ruling out ligand exchange as the switching mechanism.\",\n      \"method\": \"NMR structure determination; EXAFS/XANES spectroscopy; NOESY of methylated Ada/DNA complexes\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure combined with EXAFS/XANES and DNA-binding studies\",\n      \"pmids\": [\"11284682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal and solution structures of the Cys-methylated N-terminal Ada chemosensor domain bound to DNA revealed a zinc- and methylation-dependent electrostatic switch: transfer of a methyl group from a phosphotriester to Cys-69 reorganizes the electrostatic surface of Ada, enabling sequence-specific DNA binding and transcriptional activation.\",\n      \"method\": \"X-ray crystallography and NMR solution structure of methylated Ada/DNA co-complex\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — X-ray and NMR structures with functional validation, single comprehensive study\",\n      \"pmids\": [\"16209950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In ADA-SCID patient T cells, ADA deficiency causes intrinsically reduced ZAP-70 phosphorylation, Ca2+ flux, and ERK1/2 signaling after TCR/CD28 stimulation, and exposure to 2′-deoxyadenosine causes additional T-cell activation inhibition via aberrant A2A adenosine receptor/PKA hyperactivation or direct apoptosis at higher doses. Gene therapy restoring ADA expression rescued these signaling defects.\",\n      \"method\": \"Biochemical signaling assays (phospho-ZAP-70, Ca2+ flux, ERK1/2, CREB, NF-κB) in primary T cells from ADA-SCID patients before and after gene therapy\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal signaling assays in patient cells with gene therapy rescue, single study\",\n      \"pmids\": [\"18218852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Human ADA1 and ADA2 bind to distinct subsets of immune cells: ADA1 binds CD26-expressing cells whereas ADA2 binds neutrophils, monocytes, NK cells, B cells, and CD39+ regulatory T cells that lack CD26. ADA1 preferentially binds CD16− monocytes while ADA2 binds CD16+ monocytes.\",\n      \"method\": \"Flow cytometry binding studies using purified ADA1 and ADA2 on human immune cell subsets; analysis of ADA2-deficient patient blood samples\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding experiments on defined cell populations with patient validation\",\n      \"pmids\": [\"27663683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ADA1 expressed as a cytoplasmic enzyme in CAR T cells converts adenosine to inosine; autocrine secretion of ADA1 upon CD3/CD26 stimulation activates CAR T cells, improving migration and resistance to TGF-β1 suppression, enabling inosine to serve as an alternative metabolic fuel.\",\n      \"method\": \"Engineering of CAR T cells expressing membrane-bound CD26 and cytoplasmic ADA1; in vitro functional assays and in vivo mouse tumor models\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined molecular engineering with multiple functional readouts and in vivo validation\",\n      \"pmids\": [\"38688275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ADA deficiency in mice causes a bone phenotype characterized by RANKL/OPG imbalance (decreased osteoclastogenesis) and intrinsic osteoblast dysfunction. In vitro, ADA-deficient osteoblasts show altered transcriptional profiles and reduced growth. Treatment with enzyme replacement therapy, bone marrow transplantation, or gene therapy fully restores bone parameters.\",\n      \"method\": \"ADA-deficient mouse model; in vitro osteoblast cultures; RANKL/OPG measurements; treatment rescue experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function mouse model with defined cellular phenotype and multi-modality rescue\",\n      \"pmids\": [\"19633200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ADA deficiency in mice causes neurological and behavioral abnormalities (reduced activity, anxiety-like behavior) coinciding with metabolic alterations and aberrant adenosine receptor signaling in the brain. PEG-ADA enzyme replacement corrected metabolic adenosine-based alterations but not cellular and signaling defects, indicating intrinsic neurological involvement.\",\n      \"method\": \"Behavioral tests; molecular and metabolic analyses in ADA-deficient mice; PEG-ADA treatment; adenosine receptor signaling measurements\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mouse loss-of-function model with multiple orthogonal readouts and partial rescue\",\n      \"pmids\": [\"28074903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"The human ADA gene is localized to chromosome 20q13–qter, established by somatic cell hybridization using a cell line with a 17/20 balanced translocation.\",\n      \"method\": \"Somatic cell hybridization; enzymatic detection of ADA in hybrid clones\",\n      \"journal\": \"Annals of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal localization experiment\",\n      \"pmids\": [\"6370091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"In ADA-SCID cell lines, the ADA gene structure and mRNA transcription/processing are normal, but the translated ADA protein has a subtly altered configuration that abolishes both enzymatic and immunological characteristics, demonstrating that ADA deficiency in these patients results from a protein-level defect rather than transcriptional or translational failure.\",\n      \"method\": \"ADA cDNA Southern blot; in vitro translation of ADA mRNA; immunoprecipitation with ADA antiserum\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple molecular methods in patient cell lines\",\n      \"pmids\": [\"6198631\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Human ADA (adenosine deaminase 1) is a purine-metabolizing enzyme that deaminates adenosine and 2′-deoxyadenosine to inosine and 2′-deoxyinosine; its deficiency causes toxic accumulation of deoxyadenosine metabolites that selectively impairs lymphocyte development and TCR signaling (via ZAP-70, Ca2+, ERK1/2, and A2A receptor/PKA pathways), causes RANKL/OPG imbalance affecting bone remodeling, and disrupts brain adenosine receptor signaling—while the bacterial ortholog E. coli Ada additionally functions as a bifunctional DNA repair methyltransferase (repairing O6-methylguanine via Cys-321 and methyl phosphotriesters via Cys-69) whose N-terminal domain undergoes a zinc- and methylation-dependent electrostatic switch upon Cys-69 methylation to become a class I transcriptional activator of the adaptive response regulon.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper, then extract discoveries only from KEEP papers.\n\n**Classification:**\n\nThe gene ADA here refers to human Adenosine Deaminase (ADA, EC 3.5.4.4), the purine metabolism enzyme whose deficiency causes ADA-SCID.\n\nPapers about **American Diabetes Association (ADA)** → EXCLUDE (alias collision)\nPapers about **E. coli Ada protein** (DNA repair/transcription regulator) → EXCLUDE (symbol collision - fundamentally different protein: DNA methyltransferase/transcriptional regulator, not adenosine deaminase)\nPapers about **yeast Ada/SAGA complex** (transcriptional adaptor) → EXCLUDE (symbol collision - different protein family)\nPapers about **ADA clade cyanobacteria** → EXCLUDE\nPapers about **ADA (andrographolide derivative)** → EXCLUDE\nPapers about **ADA-GEL (alginate dialdehyde)** → EXCLUDE\nPapers about **A-DA'D-A organic phototheranostics** → EXCLUDE\nPapers about **anti-drug antibodies (ADA)** → EXCLUDE\nPapers about canonical human ADA (adenosine deaminase) → KEEP\n\n**KEEP papers:**\n- PMID:12089448 (ADA-SCID gene therapy)\n- PMID:7570000 (ADA gene therapy lymphocytes/bone marrow)\n- PMID:9662367 (ADA gene therapy cord blood)\n- PMID:17671653 (ADA-SCID HSC gene therapy)\n- PMID:28396566 (ADA-SCID gene therapy approval)\n- PMID:19638621 (How I treat ADA deficiency)\n- PMID:27663683 (ADA1 and ADA2 bind different immune cells)\n- PMID:23897810 (ADA1 in neonatal blood)\n- PMID:28842866 (ADA-SCID molecular pathogenesis)\n- PMID:19633200 (ADA deficiency bone phenotype)\n- PMID:38688275 (CAR T cells with ADA1 and CD26)\n- PMID:35671392 (ADA-SCID outcomes PIDTC)\n- PMID:26038697 (ADA1 metabolism of cordycepin)\n- PMID:28074903 (ADA deficiency neurological)\n- PMID:18218852 (T-cell dysfunction ADA-SCID)\n- PMID:6198631 (ADA deficiency SCID protein aberration)\n- PMID:7749407 (PEG-ADA therapy)\n- PMID:6370091 (ADA chromosomal localization)\n- PMID:8101391 (ADA binds CD26) - KEEP\n- PMID:9247966 (cell surface ADA ectoenzyme) - KEEP\n- PMID:15983379 (CD26, ADA, adenosine receptors immunological synapse) - KEEP\n- PMID:20453107 (ADA2 monocyte differentiation) - KEEP\n- PMID:16221767 (ADA genetic variant deep sleep) - KEEP\n- PMID:24257613 (ADA antagonist DPP4/MERS-CoV) - KEEP\n- PMID:16670267 (endothelial ADA catabolism hypoxia) - KEEP\n- PMID:3839456 (ADA gene structure/promoter) - KEEP\n- PMID:3028473 (complete ADA gene sequence) - KEEP\n- PMID:10506947 (ADA histochemical/purine enzymes) - KEEP\n- PMID:17287605 (ADA G22A polymorphism CAD) - KEEP\n- PMID:17340203 (ADA G22A autism) - KEEP\n- PMID:2081198 (ADA gene therapy protocol) - KEEP\n- PMID:7570001 (T lymphocyte gene therapy ADA-SCID) - KEEP\n- PMID:1325209 (ADA gene transfer immune functions) - KEEP\n- PMID:9414266 (ADA gene therapy Japanese patient) - KEEP\n- PMID:31989577 (elapegademase vs pegademase) - KEEP\n- PMID:32880085 (USIDNet ADA-SCID registry) - KEEP\n- PMID:28847159 (25 years ADA gene therapy) - KEEP\n- PMID:28194615 (How we manage ADA SCID) - KEEP\n- PMID:29744787 (ADA deficiency clinical/lab features) - KEEP\n- PMID:26376800 (ADA deficiency single center) - KEEP\n- PMID:24076575 (ADA-SCID newborn screening) - KEEP\n- PMID:21624848 (RAG1/2 and ADA mutations) - KEEP\n- PMID:28351939 (cytoreductive conditioning ADA-SCID) - KEEP\n- PMID:38688902 (T-ALL in ADA-SCID gene therapy) - KEEP\n- PMID:12435054 (advances gene therapy ADA-SCID) - KEEP\n- PMID:32156055 (ADA in fibroblasts adenosine/inosine) - KEEP\n- PMID:32043202 (fluorescent detection ADA) - KEEP (biosensor, not mechanistic about ADA protein)\n- PMID:36309141 (ADA/XO/UA pathway HAART) - borderline, about ADA enzyme activity in context\n- PMID:35420773 (A-DA'D-A phototheranostics) - EXCLUDE\n- PMID:38185066 (ADA andrographolide derivative) - EXCLUDE\n- PMID:34023075 (ADA clade cyanobacteria) - EXCLUDE\n\nNow extracting mechanistic discoveries from KEEP papers:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"The human ADA gene is 32 kb long, split into 12 exons, and its promoter region lacks TATA and CAAT boxes but is extremely G/C-rich (82%), containing SP1-binding motifs (GGGCGGG); a 135 bp upstream sequence was shown to have promoter activity in functional assays.\",\n      \"method\": \"Cosmid clone isolation, DNA sequencing, functional promoter assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct sequencing of the gene and functional promoter assay in original characterization paper\",\n      \"pmids\": [\"3839456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"The complete human ADA gene sequence confirmed 12 exons over 36,741 bp, with a G/C-rich promoter lacking TATA/CAAT boxes containing six SP1 binding site homologs (GGGCGGG), and defined all intron-exon boundaries.\",\n      \"method\": \"DNA sequencing of overlapping lambda phage clones\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete gene sequence with functional annotation\",\n      \"pmids\": [\"3028473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"ADA deficiency in ADA-SCID cells is not due to transcriptional or translational defects but to subtle changes in protein configuration affecting both enzymatic and immunological characteristics, as ADA-specific mRNA from SCID cells could be translated in vitro into a protein of normal molecular weight that lacked immunoprecipitability with ADA antiserum.\",\n      \"method\": \"Northern blot analysis, in vitro translation, immunoprecipitation\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (translation assay + immunoprecipitation) demonstrating protein-level defect\",\n      \"pmids\": [\"6198631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"The human ADA gene was regionally localized to chromosome 20q13.2–qter by somatic cell hybridization using a human cell line with a 17/20 balanced translocation.\",\n      \"method\": \"Somatic cell hybridization, enzyme assay\",\n      \"journal\": \"Annals of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal localization confirmed by hybrid clone analysis\",\n      \"pmids\": [\"6370091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"ADA directly associates with CD26 (dipeptidyl peptidase IV, DPPIV) on the T cell surface; this 43 kDa protein was identified as ADA by amino acid sequence analysis and confirmed by immunoprecipitation, with binding mediated through the extracellular domain of CD26.\",\n      \"method\": \"Amino acid sequencing, immunoprecipitation, in vitro binding assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical identification by sequencing plus reciprocal binding assay, highly cited foundational paper\",\n      \"pmids\": [\"8101391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"ADA functions as an ectoenzyme on the cell surface by binding to membrane proteins including CD26 and A1 adenosine receptors (A1R); surface-bound ADA transmits signals upon interaction with CD26 or A1R, acting as a co-stimulatory molecule that facilitates specific signaling events, and its heterogeneous distribution in the nervous system suggests a neuroregulatory role.\",\n      \"method\": \"Cell surface binding studies, signal transduction assays, immunohistochemistry\",\n      \"journal\": \"Progress in neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple binding and signaling assays but largely review/synthesis of experimental work\",\n      \"pmids\": [\"9247966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ADA bound to CD26 on T cells interacts with an ADA-anchoring protein on dendritic cells to form a costimulatory signal at the immunological synapse; this costimulation was not due to ADA enzymatic activity but to protein-protein interaction, and potentiated T cell proliferation and production of IFN-γ, TNF-α, and IL-6 by 3- to 34-fold.\",\n      \"method\": \"Autologous T cell/dendritic cell coculture, colocalization microscopy, cytokine measurement, EC50 analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (colocalization, functional assays, enzymatic activity controls) replicated across cell types\",\n      \"pmids\": [\"15983379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"During hypoxia, endothelial ADA expression and activity are induced, and CD26 is coordinately upregulated to localize ADA activity at the endothelial cell surface; ADA surface binding was blocked by gp120 (which competes for ADA-CD26 binding), and pharmacological ADA inhibition with deoxycoformycin enhanced adenosine-mediated protection (reduced vascular leak and neutrophil accumulation) in murine hypoxia models.\",\n      \"method\": \"Microarray, in vitro/in vivo hypoxia models, protein expression, ADA activity assay, gp120 competition, deoxycoformycin pharmacological inhibition, plasma ADA activity in pediatric patients\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro and in vivo methods with mechanistic follow-up including pharmacological inhibition and patient samples\",\n      \"pmids\": [\"16670267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In ADA-SCID patients, CD4+ T cells have severely compromised TCR/CD28-driven proliferation associated with intrinsically reduced ZAP-70 phosphorylation, Ca2+ flux, and ERK1/2 signaling, and defective CREB and NF-κB transcriptional activity; exposure to 2'-deoxyadenosine additionally inhibits T cell activation via aberrant A2A adenosine receptor signaling and PKA hyperactivation, or induces apoptosis at higher doses; gene therapy restored these biochemical signaling events and T cell functions.\",\n      \"method\": \"Phosphorylation assays, Ca2+ flux measurements, ERK1/2 signaling, transcription factor assays, apoptosis assays, receptor signaling pharmacology, comparison pre/post gene therapy\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical methods in primary patient cells with mechanistic rescue by gene therapy\",\n      \"pmids\": [\"18218852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ADA deficiency causes a specific bone phenotype in mice characterized by an imbalanced RANKL/osteoprotegerin axis (decreased osteoclastogenesis) and intrinsic osteoblast dysfunction with low bone formation; ADA-deficient osteoblasts showed altered transcriptional profile and growth reduction in vitro, and the bone marrow microenvironment had reduced capacity to support hematopoiesis; enzyme replacement, bone marrow transplantation, or gene therapy fully rescued these defects.\",\n      \"method\": \"Mouse knockout model, bone structural analysis, in vitro osteoblast assays, RANKL/OPG measurement, hematopoietic support assay, rescue experiments (ERT/BMT/GT)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in mouse model with mechanistic pathway identification and therapeutic rescue\",\n      \"pmids\": [\"19633200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ADA2 is secreted by monocytes undergoing differentiation into macrophages or dendritic cells and binds to cell surfaces via proteoglycans and adenosine receptors; ADA2 (but not ADA1) induces T cell-dependent differentiation of monocytes into macrophages and stimulates macrophage proliferation; both ADA1 and ADA2 increase proliferation of monocyte-activated CD4+ T cells independently of their catalytic deaminase activity.\",\n      \"method\": \"Cell differentiation assays, surface binding assays, proteoglycan competition, receptor blocking, T cell proliferation assays\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple binding and functional assays distinguishing catalytic vs. non-catalytic roles; ADA2-specific functions established with mechanistic controls\",\n      \"pmids\": [\"20453107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In neonatal blood, soluble ADA1 (not ADA2) is the enzyme responsible for catabolizing extracellular adenosine to inosine; neonatal plasma has substantially lower ADA activity than adult plasma, resulting in elevated extracellular adenosine concentrations in newborns; selective 5'-NT inhibition enhanced TLR-mediated TNF-α production in neonatal blood, confirming functional relevance of the adenosine-generating/catabolizing enzyme balance.\",\n      \"method\": \"Enzyme activity assays (ADA isoform-specific), plasma fractionation, pharmacological inhibition of 5'-NT, TLR stimulation/cytokine measurement in whole blood, infant cohort samples\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical and functional assays with isoform specificity established, validated in patient cohorts\",\n      \"pmids\": [\"23897810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADA acts as a natural antagonist for DPP4-mediated entry of MERS-CoV; ADA competed with MERS-CoV for DPP4 binding, and site-directed mutagenesis of ferret DPP4 residues identified the functional human DPP4 virus-binding site, which overlaps with the ADA-binding site.\",\n      \"method\": \"Site-directed mutagenesis, viral entry competition assay, receptor binding assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis combined with functional competition assay defining the shared binding site\",\n      \"pmids\": [\"24257613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ADA1-expressing HEK293 cells (but not ADA2-expressing cells) extensively metabolize cordycepin by deamination, with Km of 54.9 μmol/L and Vmax of 45.8 nmol/min/mg protein; naringin strongly inhibits ADA1-mediated cordycepin deamination (Ki ~58.8 μmol/L in mouse erythrocytes), demonstrating ADA1 is the primary isoform responsible for cordycepin metabolism.\",\n      \"method\": \"Isoform-specific overexpression in HEK293 cells, enzyme kinetics, inhibition assays (Ki determination), cytotoxicity assay\",\n      \"journal\": \"Pharmacology research & perspectives\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with isoform-specific expression and kinetic characterization\",\n      \"pmids\": [\"26038697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ADA1 and ADA2 bind to different subsets of immune cells: ADA2 binds to neutrophils, monocytes, NK cells, and B cells that do not express CD26 (the ADA1 receptor), and specifically to CD39+ regulatory T cells lacking CD26; ADA1 binds CD16- monocytes while CD16+ monocytes preferentially bind ADA2; ADA2-deficient patients show dramatic reduction in lymphocyte subsets and increased plasma TNF-α.\",\n      \"method\": \"Flow cytometry with isoform-specific binding assays, analysis of ADA2-deficient patient blood samples, cytokine measurement\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic flow cytometry binding analysis across immune cell subsets with patient validation\",\n      \"pmids\": [\"27663683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ADA deficiency in mice and patients causes neurological and behavioral abnormalities including motor dysfunction, EEG alterations, sensorineural hearing loss, and white matter alterations; ADA-deficient mice showed anxiety-like behavior coinciding with metabolic alterations and aberrant adenosine receptor signaling; PEG-ADA treatment corrected metabolic adenosine-based alterations but not cellular and signaling defects, indicating an intrinsic neurological component beyond peripheral adenosine levels.\",\n      \"method\": \"Mouse behavioral assays, EEG, MRI, metabolic/molecular analysis, adenosine receptor signaling assays, PEG-ADA treatment comparison\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in mouse and patient cohorts establishing intrinsic neurological role of ADA metabolism\",\n      \"pmids\": [\"28074903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A functional genetic variant of ADA (G22A polymorphism, Asp8Asn), which reduces ADA enzyme activity, specifically enhances deep sleep and slow-wave activity (SWA) during sleep in humans, indicating ADA-mediated adenosine metabolism directly regulates sleep homeostasis.\",\n      \"method\": \"Human genetic study, polysomnography/EEG measurement of sleep parameters, comparison with A2A receptor polymorphism\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genotype-phenotype study with specific EEG/sleep readout, isoform-specific effect confirmed by comparison with different adenosine pathway variant\",\n      \"pmids\": [\"16221767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Retroviral transfer of the ADA gene into ADA-deficient peripheral blood T lymphocytes restored ADA enzyme activity and reconstituted specific immune functions including proliferative capacity, alloreactive and antigen-specific responses in vivo in BNX immunodeficient mice, demonstrating that ADA enzymatic activity is required for T lymphocyte survival and immune function.\",\n      \"method\": \"Retroviral gene transfer, enzyme activity assay, in vivo T cell reconstitution in immunodeficient mice, TCR analysis, antigen-specific response assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional rescue by gene restoration with multiple immune function readouts\",\n      \"pmids\": [\"1325209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Engineering CAR T cells to co-express membrane-bound CD26 and cytoplasmic ADA1 enables autocrine secretion of ADA1 upon CD3/CD26 stimulation; ADA1 converts adenosine to inosine which serves as alternative fuel, improving CAR T cell migration, resistance to TGF-β1 suppression, and anti-tumor activity in hepatocellular carcinoma and non-small cell lung cancer mouse models; fusion of ADA1 with anti-CD3 scFv further boosted inosine production.\",\n      \"method\": \"CAR T cell engineering, in vitro migration and suppression assays, mouse tumor models (HCC and NSCLC), ADA1 enzymatic activity assays\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic engineering study with in vitro and in vivo functional validation across multiple tumor models\",\n      \"pmids\": [\"38688275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Human subcutaneous fibroblasts have very low endogenous ADA activity; exogenous ADA addition converts adenosine to inosine which acts through A3 receptors to decrease fibroblast growth and collagen production, opposing the pro-collagen effects of adenosine acting via A2A receptors, demonstrating that ADA-expressing inflammatory cells (third-party ADA providers) can regulate dermal remodeling by controlling the adenosine/inosine balance.\",\n      \"method\": \"Cell culture, enzyme activity assays, receptor agonist/antagonist pharmacology, collagen production assay, proliferation assay\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological dissection of ADA enzymatic role in fibroblast biology using receptor-specific antagonists\",\n      \"pmids\": [\"32156055\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Human ADA1 (adenosine deaminase 1) is a purine metabolism enzyme that deaminates adenosine and 2'-deoxyadenosine to inosine and 2'-deoxyinosine; it is encoded by a 12-exon gene on chromosome 20q13.2 with a TATA-less, G/C-rich SP1-dependent promoter, and functions both intracellularly (where its deficiency causes toxic accumulation of deoxyadenosine substrates that impair ZAP-70/ERK/NF-κB T cell signaling) and as a cell-surface ectoenzyme anchored via CD26/DPP4 (and A1/A2B adenosine receptors) where it regulates extracellular adenosine levels, provides non-enzymatic costimulatory signals at the immunological synapse, and controls sleep homeostasis; a second isoform, ADA2, is secreted by monocytes, binds different immune cell subsets via proteoglycans and adenosine receptors, and promotes macrophage differentiation and proliferation independently of its catalytic activity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ADA (adenosine deaminase 1) is a purine-metabolizing enzyme that catalyzes the irreversible deamination of adenosine and 2′-deoxyadenosine to inosine and 2′-deoxyinosine, playing essential roles in lymphocyte development, bone homeostasis, and neurological function. Deficiency of ADA causes severe combined immunodeficiency (ADA-SCID) through toxic accumulation of deoxyadenosine metabolites that intrinsically impair TCR signaling—reducing ZAP-70 phosphorylation, Ca²⁺ flux, and ERK1/2 activation—and through aberrant A2A adenosine receptor/PKA hyperactivation, with gene therapy restoring these defects [PMID:18218852, PMID:6198631]. Beyond immunity, ADA deficiency disrupts RANKL/OPG balance causing osteoblast dysfunction and impaired bone remodeling [PMID:19633200], and produces neurological abnormalities linked to aberrant adenosine receptor signaling that are only partially corrected by enzyme replacement [PMID:28074903]. ADA1 binds CD26-expressing immune cells and, when expressed in engineered CAR T cells, converts immunosuppressive adenosine to inosine, enhancing T-cell activation and providing an alternative metabolic fuel [PMID:27663683, PMID:38688275].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Establishing the genomic locus and molecular basis of ADA-SCID: the human ADA gene was mapped to chromosome 20q13–qter, and patient cell lines revealed that ADA-SCID results from missense-level protein defects rather than transcriptional or translational failure, framing the disease as an enzymopathy.\",\n      \"evidence\": \"Somatic cell hybridization for chromosomal localization; cDNA Southern blot, in vitro translation, and immunoprecipitation of patient ADA protein\",\n      \"pmids\": [\"6370091\", \"6198631\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific causative mutations not identified at sequence level\", \"No structural explanation for loss of enzymatic activity\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Defining the E. coli Ada protein as a bifunctional DNA repair methyltransferase with two independent catalytic domains—resolving how a single protein repairs both O⁶-methylguanine (via Cys-321) and methyl phosphotriesters (via Cys-69)—and establishing that Cys-69 methylation converts Ada into a transcriptional activator of the adaptive response regulon.\",\n      \"evidence\": \"In vitro methyltransferase assays with purified Ada; limited proteolysis domain mapping; site-directed mutagenesis of Cys-69 and Cys-321; in vitro and in vivo transcription assays; promoter mutagenesis identifying the Ada box sequence\",\n      \"pmids\": [\"2987862\", \"3162236\", \"3047400\", \"2843522\", \"3139888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the methylation-dependent conformational switch unknown at this point\", \"Mechanism of C-terminal domain modulation of transcriptional specificity not fully explained\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Discovery of a proteolytic mechanism for terminating the adaptive response: a cellular thiol protease cleaves Ada into separable N-terminal (phosphotriester repair) and C-terminal (O⁶-methylguanine repair) fragments, with the methylated N-terminal fragment activating alkA but repressing ada transcription.\",\n      \"evidence\": \"In vitro proteolysis of Ada; purification and activity assays of 20-kDa and 19-kDa fragments; in vitro and in vivo transcription assays\",\n      \"pmids\": [\"2254928\", \"3058696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the thiol protease not determined\", \"In vivo kinetics and regulation of Ada proteolysis unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Revealing a dual regulatory logic: unmethylated Ada negatively autoregulates ada (but not alkA) transcription via its C-terminal 67 residues, and NMR confirmed that methylated Cys-69 remains zinc-coordinated in the active Ada–DNA complex, ruling out ligand exchange as the activation mechanism.\",\n      \"evidence\": \"In vitro transcription with C-terminal deletion mutants; in vivo reporter assays; ¹³C-labeled NMR of methylated Ada\",\n      \"pmids\": [\"7937881\", \"9383376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution structure of methylated Ada bound to DNA not yet available\", \"How unmethylated Ada inhibition is relieved during sustained alkylation stress unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Solving the structural mechanism of the Ada chemosensor: crystal and NMR structures of methylated N-Ada bound to DNA revealed a zinc- and methylation-dependent electrostatic switch in which methyl transfer to Cys-69 reorganizes the protein's electrostatic surface to enable sequence-specific DNA recognition.\",\n      \"evidence\": \"X-ray crystallography and NMR solution structure of methylated Ada/DNA co-complex; EXAFS/XANES spectroscopy\",\n      \"pmids\": [\"11284682\", \"16209950\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full-length Ada–DNA–RNAP ternary complex structure\", \"Dynamics of the electrostatic switch in real-time during DNA scanning not characterized\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defining the intrinsic TCR signaling defects in human ADA-SCID: ADA deficiency causes reduced ZAP-70, Ca²⁺, and ERK1/2 signaling independent of metabolite toxicity, while deoxyadenosine additionally inhibits T cells via A2A receptor/PKA hyperactivation—establishing that immunodeficiency reflects both intrinsic signaling and metabolite-mediated mechanisms.\",\n      \"evidence\": \"Phospho-signaling assays in primary T cells from ADA-SCID patients before and after gene therapy rescue\",\n      \"pmids\": [\"18218852\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular target linking ADA absence to intrinsic ZAP-70 hypophosphorylation not identified\", \"Single study; independent replication in larger patient cohorts needed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extending ADA function beyond immunity: ADA-deficient mice revealed a bone phenotype with RANKL/OPG imbalance and intrinsic osteoblast dysfunction, correctable by enzyme replacement, transplantation, or gene therapy.\",\n      \"evidence\": \"ADA-deficient mouse model; in vitro osteoblast cultures; RANKL/OPG measurements; multi-modality rescue\",\n      \"pmids\": [\"19633200\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular mechanism linking adenosine/deoxyadenosine accumulation to osteoblast transcriptional changes unknown\", \"Human bone phenotype characterization limited\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating that ADA deficiency causes neurological abnormalities through aberrant adenosine receptor signaling in the brain, and that enzyme replacement only partially rescues these defects—indicating cell-intrinsic neuronal damage.\",\n      \"evidence\": \"Behavioral tests and molecular/metabolic analyses in ADA-deficient mice with PEG-ADA treatment\",\n      \"pmids\": [\"28074903\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific neuronal cell types and adenosine receptor subtypes driving the phenotype not defined\", \"Whether early treatment prevents irreversible neurological damage unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Translating ADA1 enzymology into immunotherapy: engineered expression of ADA1 in CAR T cells converts immunosuppressive adenosine to inosine, enhancing T-cell activation, migration, and resistance to TGF-β1 suppression in the tumor microenvironment.\",\n      \"evidence\": \"CAR T cells engineered with ADA1/CD26; in vitro functional assays and in vivo mouse tumor models\",\n      \"pmids\": [\"38688275\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Long-term safety and efficacy in human trials not established\", \"Whether inosine utilization as metabolic fuel is limiting in vivo unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the precise molecular mechanism by which ADA absence intrinsically impairs ZAP-70 phosphorylation, the identity and regulation of the thiol protease that cleaves bacterial Ada to terminate the adaptive response, and whether ADA's non-immune functions (bone, brain) are mediated through specific adenosine receptor subtypes or distinct metabolic pathways.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No substrate-level explanation for intrinsic TCR signaling defect in ADA-SCID\", \"Thiol protease identity unknown\", \"Relative contributions of specific adenosine receptors to bone and brain phenotypes undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [14, 15, 16, 17, 18]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 2, 5, 9]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [5, 12, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0073894\", \"supporting_discovery_ids\": [0, 1, 2, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [14, 15, 16]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [14, 16, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CD26\",\n      \"ZAP70\",\n      \"ADORA2A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ADA (adenosine deaminase 1) is a purine-metabolizing enzyme that catalyzes the irreversible deamination of adenosine and 2′-deoxyadenosine to inosine and 2′-deoxyinosine, functioning both intracellularly to prevent toxic substrate accumulation and extracellularly as an ectoenzyme anchored to the cell surface via CD26/DPP4 and adenosine receptors, where it regulates local adenosine concentrations and provides catalysis-independent costimulatory signals at the immunological synapse [PMID:8101391, PMID:15983379, PMID:23897810]. ADA deficiency causes severe combined immunodeficiency (SCID) through impaired T-cell receptor signaling—specifically reduced ZAP-70 phosphorylation, Ca²⁺ flux, ERK1/2 activation, and NF-κB transcriptional activity—as well as skeletal defects from osteoblast dysfunction and neurological abnormalities linked to aberrant adenosine receptor signaling, defects that are correctable by gene therapy or enzyme replacement [PMID:18218852, PMID:19633200, PMID:28074903]. A common functional polymorphism (G22A/Asp8Asn) that reduces ADA activity enhances slow-wave sleep in humans, establishing ADA-mediated adenosine catabolism as a direct regulator of sleep homeostasis [PMID:16221767]. ADA also competitively inhibits MERS-CoV binding to its receptor DPP4/CD26, and its inosine product can serve as an alternative metabolic fuel for T cells in immunosuppressive tumor microenvironments [PMID:24257613, PMID:38688275].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Establishing the chromosomal locus and nature of ADA-SCID mutations resolved whether deficiency arose from transcriptional silencing or protein-level dysfunction, showing that SCID cells produce ADA mRNA encoding a structurally altered, catalytically inactive protein.\",\n      \"evidence\": \"Northern blot, in vitro translation, and immunoprecipitation of SCID-derived ADA mRNA products; somatic cell hybridization mapped ADA to 20q13.2\",\n      \"pmids\": [\"6198631\", \"6370091\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific point mutations causing misfolding were not identified\", \"No structural basis for loss of immunoreactivity\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Complete gene characterization revealed an unusual TATA-less, GC-rich promoter architecture with SP1-dependent regulation, defining the transcriptional control elements of ADA and enabling future gene therapy vector design.\",\n      \"evidence\": \"Cosmid/phage clone sequencing and functional promoter assays identified 12 exons over ~32–37 kb with six SP1-binding motifs\",\n      \"pmids\": [\"3839456\", \"3028473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type-specific enhancer elements not characterized\", \"Regulation of tissue-variable ADA expression not explained by promoter alone\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identification of CD26/DPP4 as the surface anchor for ADA transformed understanding of ADA from a purely intracellular metabolic enzyme to a cell-surface ectoenzyme, opening the field of ADA-mediated cell signaling.\",\n      \"evidence\": \"Amino acid sequencing of the 43-kDa CD26-associated protein, reciprocal immunoprecipitation, and in vitro binding assays\",\n      \"pmids\": [\"8101391\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and affinity of the ADA–CD26 complex not quantified\", \"Whether ADA binding modulates CD26 peptidase activity was unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Extension of ADA surface-binding partners beyond CD26 to include A1 adenosine receptors broadened the ectoenzyme concept to include neuromodulatory contexts, suggesting ADA regulates adenosine tone at neuronal surfaces.\",\n      \"evidence\": \"Cell surface binding studies, signal transduction assays, and immunohistochemistry across neural tissues\",\n      \"pmids\": [\"9247966\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct in vivo demonstration of ADA–A1R complex function in neurons was lacking\", \"Relative contribution of A1R vs. CD26 anchoring in different tissues unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Two concurrent breakthroughs established non-enzymatic functions and physiological endpoints: ADA at the immunological synapse provides catalysis-independent costimulation amplifying cytokine production, while a human ADA polymorphism (Asp8Asn) that reduces enzymatic activity directly modulates sleep depth.\",\n      \"evidence\": \"Autologous T cell/DC cocultures with catalytically inactive ADA controls showed 3–34-fold cytokine enhancement; genotype-phenotype study with polysomnography linked G22A to enhanced slow-wave activity\",\n      \"pmids\": [\"15983379\", \"16221767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the dendritic-cell ADA-anchoring protein at the synapse unresolved\", \"Mechanism linking reduced ADA activity to increased slow-wave sleep not defined at the molecular level\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Molecular dissection of ADA-SCID T cells pinpointed the signaling defects—impaired ZAP-70 phosphorylation, Ca²⁺ flux, ERK1/2, CREB, and NF-κB—and showed that deoxyadenosine additionally suppresses T cells through aberrant A2A receptor/PKA signaling; gene therapy rescued all these biochemical defects.\",\n      \"evidence\": \"Phospho-flow, Ca²⁺ flux, transcription factor assays, and apoptosis assays in ADA-SCID patient T cells pre- and post-gene therapy\",\n      \"pmids\": [\"18218852\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of intracellular dATP accumulation vs. extracellular deoxyadenosine signaling not fully deconvoluted\", \"Threshold of ADA restoration needed for full signaling recovery not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery of a bone phenotype in ADA-deficient mice—imbalanced RANKL/OPG axis and intrinsic osteoblast dysfunction—expanded the disease spectrum beyond immunodeficiency and showed the bone marrow microenvironment depends on purine homeostasis for hematopoietic support.\",\n      \"evidence\": \"ADA-knockout mouse bone analysis, in vitro osteoblast assays, RANKL/OPG quantification, rescue by ERT/BMT/gene therapy\",\n      \"pmids\": [\"19633200\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific metabolites (adenosine vs. deoxyadenosine) responsible for osteoblast dysfunction not distinguished\", \"Human bone phenotype not systematically characterized\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Two advances clarified isoform-specific biology: ADA1 (not ADA2) is the dominant extracellular adenosine-catabolizing enzyme in plasma, and ADA competes with MERS-CoV for the DPP4/CD26 binding site, revealing an unexpected antiviral role.\",\n      \"evidence\": \"Isoform-specific enzyme assays in fractionated neonatal/adult plasma; site-directed mutagenesis and viral entry competition assays for MERS-CoV–DPP4 interaction\",\n      \"pmids\": [\"23897810\", \"24257613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of ADA–DPP4 competition for MERS-CoV infection not tested in animal models\", \"Whether low neonatal ADA1 activity contributes to neonatal infection susceptibility not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Systematic mapping of ADA1 and ADA2 binding to immune cell subsets revealed complementary distribution: ADA1 binds CD26⁺ cells (including CD16⁻ monocytes) while ADA2 binds CD26⁻ cells (neutrophils, NK cells, B cells, CD39⁺ Tregs), establishing non-redundant immunomodulatory roles for each isoform.\",\n      \"evidence\": \"Flow cytometry with isoform-specific binding, validated in ADA2-deficient patient samples showing lymphocyte depletion and elevated TNF-α\",\n      \"pmids\": [\"27663683\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the ADA2 surface receptor on CD26⁻ cells not fully defined beyond proteoglycans/adenosine receptors\", \"Functional consequences of ADA2 binding to specific subsets (e.g., Tregs) not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Neurological abnormalities in ADA-deficient mice and patients—motor dysfunction, EEG alterations, hearing loss, white matter changes—persist after enzyme replacement, revealing an intrinsic CNS component of ADA deficiency not correctable by peripheral adenosine normalization.\",\n      \"evidence\": \"Behavioral, EEG, MRI, and molecular analyses in ADA-knockout mice with PEG-ADA treatment, cross-referenced with patient neurological data\",\n      \"pmids\": [\"28074903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether neurological defects arise during a critical developmental window or are ongoing not resolved\", \"Blood-brain barrier penetration of PEG-ADA not measured\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Engineered co-expression of ADA1 and CD26 in CAR T cells demonstrated that ADA1-generated inosine serves as alternative fuel and confers resistance to adenosine-mediated and TGF-β1-mediated immunosuppression in the tumor microenvironment, translating decades of basic ADA biology into therapeutic application.\",\n      \"evidence\": \"CAR T cell engineering with membrane CD26 and cytoplasmic ADA1, validated by migration assays, suppression resistance, and anti-tumor efficacy in HCC and NSCLC mouse models\",\n      \"pmids\": [\"38688275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term safety of constitutive ADA1 overexpression in T cells not assessed\", \"Whether inosine fuel utilization or adenosine depletion is the dominant mechanism in vivo not deconvoluted\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the dendritic-cell ADA-anchoring protein at the immunological synapse, the molecular mechanism by which ADA activity modulates sleep homeostasis, the developmental timing of irreversible CNS damage in ADA deficiency, and the structural basis for ADA1 vs. ADA2 receptor selectivity.\",\n      \"evidence\": \"Open questions synthesized from gaps across the literature\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of the ADA–A1R or ADA2–proteoglycan complex exists\", \"In vivo isoform-specific roles in different tissue niches remain poorly quantified\", \"Whether ADA1 enzymatic and costimulatory functions are separable in a therapeutic context is untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [8, 11, 13, 18, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 10, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4, 5, 6, 7, 14]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 8, 18]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [10, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 11, 13, 18, 19]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 8, 10, 14, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 6, 8, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"DPP4\",\n      \"ADORA1\",\n      \"ADORA2A\",\n      \"ADORA2B\",\n      \"ADORA3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}